Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Cash from Operations (2020 - 2025)

Historic Cash from Operations for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q3 2025 value amounting to -$10.7 million.

  • Barinthus Biotherapeutics' Cash from Operations rose 4105.95% to -$10.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$30.7 million, marking a year-over-year increase of 5026.53%. This contributed to the annual value of -$28.9 million for FY2024, which is 4317.13% up from last year.
  • As of Q3 2025, Barinthus Biotherapeutics' Cash from Operations stood at -$10.7 million, which was up 4105.95% from -$18.1 million recorded in Q2 2025.
  • In the past 5 years, Barinthus Biotherapeutics' Cash from Operations registered a high of $13.1 million during Q4 2024, and its lowest value of -$19.6 million during Q4 2023.
  • For the 5-year period, Barinthus Biotherapeutics' Cash from Operations averaged around -$9.0 million, with its median value being -$11.2 million (2023).
  • In the last 5 years, Barinthus Biotherapeutics' Cash from Operations plummeted by 143936.84% in 2021 and then skyrocketed by 68889.99% in 2022.
  • Quarter analysis of 5 years shows Barinthus Biotherapeutics' Cash from Operations stood at -$8.0 million in 2021, then tumbled by 42.29% to -$11.3 million in 2022, then crashed by 72.82% to -$19.6 million in 2023, then skyrocketed by 166.76% to $13.1 million in 2024, then plummeted by 181.97% to -$10.7 million in 2025.
  • Its last three reported values are -$10.7 million in Q3 2025, -$18.1 million for Q2 2025, and -$14.9 million during Q1 2025.